植入式心律转复除颤器电击后生存:五项里程碑试验分析
该研究纳入5项ICD里程碑试验的5516例受者,采用4种时依模型分析器械治疗与后续死亡的关系。结果显示,恰当ICD电击与死亡风险增加相关,而不恰当电击单独无显著关联;室速≥200次/分或室颤的治疗与死亡风险增加相关,室速<200次/分的恰当治疗未达统计学显著。结论提示,潜在心律失常基质而非ICD治疗本身是死亡更重要的决定因素。
要点
- 恰当ICD电击与后续死亡风险增加相关,不恰当电击单独无显著关联。
- 室速≥200次/分或室颤的ICD治疗与死亡风险增加相关。
- 室速<200次/分的恰当治疗未达统计学显著。
核心结论
- 潜在心律失常基质而非ICD治疗本身是ICD受者死亡更重要的决定因素。
研究设计与样本
- 研究队列包括5516例ICD受者,来自5项里程碑ICD试验(MADIT-II、MADIT-RISK、MADIT-CRT、MADIT-RIT、RAID)。
- 采用4种时依模型分析器械治疗与后续死亡的关联:模型I为ICD治疗类型;模型II为ICD治疗的心律失常类型;模型III为随访期间所有心律失常和治疗类型的联合评估;模型IV为重复ICD电击的增量风险。
主要发现
- 模型I中,首次恰当ICD电击与后续死亡风险增加相关,无论随访期间是否合并不恰当电击(HR分别为2.78和2.31;p<0.001和p=0.12),而不恰当电击单独与死亡风险无关(HR:1.23;p=0.42)。
- 模型II中,室速≥200次/分或室颤的ICD治疗与死亡风险增加相关,无论是否合并室速<200次/分的治疗(HR分别为2.25和2.62;均p<0.001),而室速<200次/分的恰当治疗或不恰当治疗(无论病因)均未达统计学显著(均p>0.10)。
- 模型III显示,室颤的恰当ICD电击、快速室速(≥200次/分)无先前抗心动过速起搏(ATP)的电击、以及ATP失败后快速室速的电击,与后续死亡最高风险相关(HR均>2.8;p<0.001)。
- 模型IV中,2次或以上恰当ICD电击与首次恰当ICD电击相比未增加增量风险。
临床怎么用
- ICD受者发生恰当电击(尤其室颤或快速室速)提示死亡风险增加,应加强风险分层与随访管理。
- 不恰当电击单独不显著增加死亡风险,但需关注其临床意义并优化器械设置。
局限性
- 研究基于5项里程碑ICD试验的队列数据,结果可能受原始试验入组标准影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are conflicting data on the impact of implantable cardioverter-defibrillator (ICD) shocks on subsequent mortality. OBJECTIVES: The aim of this study was to determine whether the arrhythmic substrate leading to ICD therapy or the therapy itself increases mortality. METHODS: The study cohort included 5,516 ICD recipients who were enrolled in 5 landmark ICD trials (MADIT-II, MADIT-RISK, MADIT-CRT, MADIT-RIT, RAID). The authors evaluated the association of device therapy with subsequent mortality in 4 separate time-dependent models: model I, type of ICD therapy; model II, type of arrhythmia for which ICD therapy was delivered; model III, combined assessment of all arrhythmia and therapy types during follow-up; and model IV, incremental risk associated with repeated ICD shocks. RESULTS: When analyzed by the type of ICD therapy (model I), a first appropriate ICD shock was associated with increased risk of subsequent mortality with or without concomitant occurrence of inappropriate shock during follow-up (hazard ratio [HR]: 2.78 and 2.31; p < 0.001 and p = 0.12), whereas inappropriate shock alone was not associated with mortality risk (HR: 1.23; p = 0.42). Similarly, ICD therapy for ventricular tachycardia (VT) ≥200 beats/min or ventricular fibrillation (VF) (model II) was associated with increased risk of death with or without concomitant therapy for VT <200 beats/min (HRs: 2.25 and 2.62; both p < 0.001), whereas appropriate therapy for VT <200 beats/min or inappropriate therapy (regardless of etiology) did not reach statistical significance (all p > 0.10). Combined assessment of all therapy and arrhythmia types during follow-up (model III) showed that appropriate ICD shocks for VF, shocks for fast VT (≥200 beats/min) without prior antitachycardia pacing (ATP), as well as shocks for fast VT delivered after failed ATP, were associated with the highest risk of subsequent death (HR: all >2.8; p < 0.001). Finally, 2 or more ICD appropriate shocks were not associated with incremental risk to the first appropriate ICD shock (model IV). CONCLUSION: The combined data from 5 landmark ICD trials suggest that the underlying arrhythmic substrate rather than the ICD therapy is the more important determinant of mortality in ICD recipients.
引用
- Aktaş MK, Younis A, Zareba W, et al. Survival After Implantable Cardioverter-Defibrillator Shocks. J Am Coll Cardiol. 2021. PMID: 34016257. doi:10.1016/j.jacc.2021.03.329
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。